Changes in mental health, wellbeing and personality following ayahuasca consumption: Results of a naturalistic longitudinal study
In a naturalistic longitudinal study of 53 ayahuasca‑naïve attendees, a single facilitated ceremony produced broad 1‑month improvements in depression, anxiety, stress, substance use, personality traits, relationships and spirituality. Baseline characteristics—particularly high negative emotionality and body dissociation and low self‑efficacy—predicted greater benefit while facets of the mystical experience did not, indicating potential for personalised treatment and warranting randomised controlled trials.
Authors
- Daniel Perkins
- Joseph Sarris
- Paulo Barbosa
Published
Abstract
Background
Naturalistic and placebo-controlled studies suggest ayahuasca, a potent psychedelic beverage originating from Indigenous Amazonian tradition, may improve mental health, alter personality structure, and reduce alcohol and drug intake. To better understand ayahuasca’s therapeutic potential and to identify factors that influence therapeutic efficacy, we conducted a naturalistic, longitudinal study of facilitated ayahuasca consumption in naïve participants using a comprehensive battery of self-report questionnaires.
Materials and Methods
Ayahuasca naive individuals registering for ayahuasca ceremonies were asked to complete a range of validated questionnaires assessing mental health, alcohol/cannabis use, relationships, personality, and connection to self and spirituality, prior to and 1 month after attending an ayahuasca ceremony. Data for two mental health measures (the DASS-21 and PANAS) and acute subjective effectsviathe MEQ-30 were also assessed 7 days post-ceremony. Repeated measures ANOVA were used to examine pre-to-post changes, and Pearson correlations explored predictors of improvement in outcomes.
Results
Fifty-three attendees (32 women, 21 men) completed pre and post ayahuasca assessments with 55.6% of the sample reporting a complete mystical experience based on the MEQ-30. One-month post-ayahuasca, significant reductions were identified in depression, anxiety, stress, alcohol and cannabis use, body dissociation, accepting external influence, self-alienation, impulsivity, and negative affect/emotionality. Significant increases were identified in positive mood, self-efficacy, authentic living, extraversion, agreeableness, open-mindedness, spirituality, and satisfaction with relationships. While facets of the mystical experience held little predictive validity on outcome measures, baseline traits, particularly high negative emotionality and body dissociation, and low sense of self-efficacy, robustly predicted improvements in mental health and alcohol/cannabis use, and alterations in personality structure which are linked to better mental health.
Discussion
This study suggests facilitated ayahuasca consumption in naïve participants may precipitate wide-ranging improvements in mental health, relationships, personality structure, and alcohol use. Associations between baseline traits and therapeutic improvements mark an important first step toward personalized, precision-based medicine and warrant randomized controlled trials to confirm and elaborate on these findings.Contribution Statement:Longitudinal, observational studies and randomized clinical control trials suggest ayahuasca may exert therapeutic effects on mental health and alcohol/cannabis use, and alter personality structure. However, it is unclear if improvements are diagnosis-specific and factors that predict therapeutic gains have yet to be extensively elucidated. This longitudinal, observational study examined the effects of facilitated ayahuasca consumption in naive participants on mental health, alcohol and substance use/abuse, personality traits, relationships, and connection to self and spirituality. We found wide-ranging improvements 1-month post-treatment across these domains, and identified baseline traits which predict pre-to-post changes on primary outcome measures. Improvements were not diagnostic-specific, suggesting ayahuasca may be generally efficacious. Personality traits, body dissociation, and self-efficacy were strong predictors of therapeutic improvements, marking an important first step toward personalized, precision-based medicine. Randomized controlled trials are warranted to confirm and elaborate on these findings.
Research Summary of 'Changes in mental health, wellbeing and personality following ayahuasca consumption: Results of a naturalistic longitudinal study'
Introduction
Ayahuasca is a traditional Amazonian psychedelic brew containing N,N-dimethyltryptamine (DMT) and harmala alkaloids that has spread from Indigenous ceremonial contexts into international therapeutic and spiritual settings. Earlier placebo-controlled, preclinical, observational, and cross-sectional studies have reported antidepressant and anxiolytic effects, reductions in substance use, and shifts in personality traits such as increased openness and agreeableness and reduced neuroticism. However, uncertainty remains about which participant characteristics predict therapeutic benefit, how personality change relates to clinical outcomes, and how findings from controlled trials generalise to naturalistic ceremonial settings. Perkins and colleagues designed a naturalistic longitudinal study to address these gaps by assessing ayahuasca-naïve adults before and after attendance at facilitated neo-shamanic ceremonies. The study aimed to measure changes in mental health, substance use, personality, relationships, self-connection, and spirituality, and to explore whether acute subjective effects (measured by the Mystical Experience Questionnaire) or baseline traits predict longer-term improvements. The authors frame this observational approach as a way to gather ecologically valid, real-world evidence to inform clinical research and public health considerations for ayahuasca use.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Create a free account to open full-text PDFs.
Study Details
- Study Typeindividual
- Journal
- Compound
- Topics
- Authors
- APA Citation
Perkins, D., Pagni, B. A., Sarris, J., Barbosa, P. C. R., & Chenhall, R. (2022). Changes in mental health, wellbeing and personality following ayahuasca consumption: Results of a naturalistic longitudinal study. Frontiers in Pharmacology, 13. https://doi.org/10.3389/fphar.2022.884703
References (45)
Papers cited by this study that are also in Blossom
Galvão-Coelho, N. L., de Almeida, R. N., de Menezes Galvão, A. C. et al. · Frontiers in Psychology (2019)
Barbosa, P., Mizumoto, S., Bogenschutz, M. P. et al. · Drug Testing and Analysis (2012)
Barbosa, P., Tófoli, L.F., Bogenschutz, M. P. et al. · Frontiers in Psychiatry (2018)
Bouso, J. C., González, D., Fondevila, S. et al. · PLOS ONE (2012)
Rodríguez-Fornells, A., Ribeiro, S., Sanches, R. F. et al. · European Neuropsychopharmacology (2015)
Cameron, L. P., Benson, C. J., Dunlap, L. E. · ACS Chemical Neuroscience (2018)
Carhart-Harris, R. L., Wagner, A. C., Agrawal, M. et al. · Journal of Psychopharmacology (2021)
Doering-Silveira, E., Grob, C. S., Dobkin de Rios, M. et al. · Journal of Psychoactive Drugs (2005)
Domínguez-Clavé, E., Soler, J., Elices, M. et al. · Human Psychopharmacology (2021)
Dos Santos, R. G., Osório, F. L., Crippa, J. A. et al. · brazilian Journal of Psychiatry (2016)
Show all 45 referencesShow fewer
Erritzoe, D., Roseman, L., Nour, M. R. et al. · Acta Psychiatrica Scandinavica (2018)
Fábregas, J. M., González, D., Fondevila, S. et al. · Drug and Alcohol Dependence (2010)
Gable, R. S. · Addiction (2006)
González, D., Cantillo, J., Perez, I. et al. · Frontiers in Pharmacology (2021)
Halpern, J. H., Sherwood, A. R., Passie, T. et al. · Medical Science Monitor (2008)
Jiménez-Garrido, D. F., Gómez-Sousa, M., Ona, G. et al. · Scientific Reports (2020)
Kiraga, M. K., Mason, N. L., Uthaug, M. V. et al. · Frontiers in Pharmacology (2021)
Lawn, W., Hallak, J. E., Crippa, J. A. et al. · Scientific Reports (2017)
Ly, C., Greb, A. C., Cameron, L. P. et al. · Cell Reports (2018)
McKenna, D. · ACS Chemical Neuroscience (2004)
McKenna, D., Towers, G. H., Abbott, F. · Journal of Ethnopharmacology (1984)
Dos Santos, R. G., Rocha, J. M., Rossi, G. N. et al. · Frontiers in Psychiatry (2021)
Morales-García, J. A., de la Fuente Revenga, M., Alonso-Gil, S. et al. · Scientific Reports (2017)
Netzband, N., Ruffell, S., Linton, &. S. et al. · Psychopharmacology (2020)
Palhano-Fontes, F., Andrade, K. C., Tófoli, L.F. et al. · PLOS ONE (2015)
Palhano-Fontes, F., Barreto, D., Onias, H. et al. · Psychological Medicine (2018)
Pallavicini, C., Cavanna, F., Zamberlan, F. et al. · Journal of Psychopharmacology (2021)
Perkins, D., Opaleye, E. S., Simonová, H. et al. · Drug and Alcohol Review (2021)
Perkins, D., Schubert, V., Simonová, H. et al. · Frontiers in Pharmacology (2021)
Rodrigues, L. S., Rossi, G. N., Rocha, J. M. et al. · European Archives of Psychiatry and Clinical Neuroscience (2021)
Roseman, L., Nutt, D. J., Carhart-Harris, R. L. · Frontiers in Pharmacology (2018)
Ruffell, S. G. D., Netzband, N., Tsang, W. et al. · Frontiers in Psychiatry (2021)
Samoylenko, V., Rahman, M. M., Tekwani, B. L. et al. · Journal of Ethnopharmacology (2010)
da Silva, F. S., Galvão-Coelho, N. L. · brazilian Journal of Psychiatry (2019)
Smigielski, L., Kometer, M., Scheidegger, M. et al. · Scientific Reports (2019)
Elices, M., Soler, J., Domínguez-Clavé, E. et al. · Frontiers in Pharmacology (2018)
Studerus, E., Gamma, A., Kometer, M. et al. · PLOS ONE (2012)
Studerus, E., Vizeli, P., Harder, S. et al. · Journal of Psychopharmacology (2021)
Thomas, G., Lucas, P., Rielle Capler, N. et al. · Current Drug Abuse Reviews (2013)
Trichter, S. · Journal of Transpersonal Psychology (2010)
Uthaug, M. V., Mason, N. L., Toennes, S. W. et al. · Psychopharmacology (2021)
van Oorsouw, K., Uthaug, M. V., Mason, N. L. et al. · Journal of Psychedelic Studies (2021)
Weiss, B., Miller, J. D., Carter, N. T. et al. · Scientific Reports (2021)
Zeifman, R. J., Dos Santos, R. G., Sanches, R. F. et al. · Psychopharmacology (2020)
MacLean, K. A., Leoutsakos, J. S., Johnson, M. W. et al. · Journal for the Scientific Study of Religion (2012)
Cited By (9)
Papers in Blossom that reference this study
Perkins, D., Halman, A., Urokohara, A. et al. · Scientific Reports (2025)
Bonomo, Y. A., Norman, A. F., Collins, L. et al. · Frontiers in Psychiatry (2025)
Pagni, B. A., Halman, A., Sarris, J. et al. · Journal of Psychoactive Drugs (2025)
Godfrey, K., Weiss, B., Zhang, X. et al. · Neuroscience Applied (2025)
Pagni, B. A., Zeifman, R. J., Mennenga, S. E. et al. · American Journal of Psychiatry (2025)
Agnorelli, C., Spriggs, M. J., Godfrey, K. et al. · Preprints (2024)
Pagni, B. A., Petridis, P. D., Podrebarac, S. K. et al. · Scientific Reports (2024)
Turkia, M. · Psyarxiv (2023)
Perkins, D., Ruffell, S. G. D., day, K. et al. · Frontiers in Neuroscience (2023)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.